title: Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP.
abstract: Neutralizing injurious stimuli, proinflammatory mediator catabolism, and polymorphonuclear leukocyte (PMN) clearance are determinants of inflammatory resolution. To this, we recently added innate-type lymphocyte repopulation as being central for restoring postinflammation tissue homeostasis with a role in controlling innate immune-mediated responses to secondary infection. However, although macrophages dominate resolution, their phenotype and role in restoring tissue physiology once inflammation abates are unknown. Therefore, we isolated macrophages from the resolving phase of acute inflammation and found that compared with classically activated proinflammatory M1 cells, resolution-phase macrophages (rMs) possess weaker bactericidal properties and express an alternatively activated phenotype but with elevated markers of M1 cells including inducible cyclooxygenase (COX 2) and nitric oxide synthase (iNOS). This phenotype is controlled by cAMP, which, when inhibited, transforms rM to M1 cells. Conversely, elevating cAMP in M1 cells transforms them to rMs, with implications for cAMP in the resolution of systemic inflammation. It transpires that although rMs are dispensable for clearing PMNs during self-limiting inflammation, they are essential for signaling postresolution lymphocyte repopulation via COX 2 lipids. Thus, rM macrophages are neither classically nor alternatively activated but a hybrid of both, with a role in mediating postresolution innate-lymphocyte repopulation and restoring tissue homeostasis.
authors.affiliation: Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom.
authors.forename: Jonas
authors.initials: J
authors.lastname: Bystrom
authors.forename: Ian
authors.initials: I
authors.lastname: Evans
authors.forename: Justine
authors.initials: J
authors.lastname: Newson
authors.forename: Melanie
authors.initials: M
authors.lastname: Stables
authors.forename: Iqbal
authors.initials: I
authors.lastname: Toor
authors.forename: Nico
authors.initials: N
authors.lastname: van Rooijen
authors.forename: Mark
authors.initials: M
authors.lastname: Crawford
authors.forename: Paul
authors.initials: P
authors.lastname: Colville-Nash
authors.forename: Stuart
authors.initials: S
authors.lastname: Farrow
authors.forename: Derek W
authors.initials: DW
authors.lastname: Gilroy
mesh_terms: D000818:Animals; D000242:Cyclic AMP / Q000276:immunology*; D051546:Cyclooxygenase 2 / Q000276:immunology; D006706:Homeostasis / Q000276:immunology*; D007113:Immunity, Innate; D007249:Inflammation / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D008262:Macrophage Activation; D017737:Macrophages, Peritoneal / Q000276:immunology*; D051379:Mice; D052247:Nitric Oxide Synthase Type II / Q000276:immunology; D020127:Recovery of Function / Q000276:immunology*
chemical_list: D000242:Cyclic AMP; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2
references.citation: J Neuroimmunol. 2000 Jun 1;105(1):31-8
references.pmid: 10713361
references.citation: J Exp Med. 1992 Jan 1;175(1):169-74
references.pmid: 1730915
references.citation: J Immunol. 1998 Sep 15;161(6):3071-6
references.pmid: 9743373
references.citation: Infect Immun. 1995 Mar;63(3):1130-3
references.pmid: 7868238
references.citation: Trends Immunol. 2004 Dec;25(12):677-86
references.pmid: 15530839
references.citation: Nat Immunol. 2005 Dec;6(12):1191-7
references.pmid: 16369558
references.citation: Lancet. 2003 Jan 11;361(9352):130-5
references.pmid: 12531580
references.citation: Nat Med. 2007 Aug;13(8):935-43
references.pmid: 17676050
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4560-5
references.pmid: 15070757
references.citation: FEMS Microbiol Lett. 2007 Apr;269(2):221-8
references.pmid: 17229058
references.citation: Nat Rev Immunol. 2005 Dec;5(12):953-64
references.pmid: 16322748
references.citation: J Leukoc Biol. 2003 Feb;73(2):209-12
references.pmid: 12554797
references.citation: Life Sci. 1974 Mar 16;14(6):1019-40
references.pmid: 4362776
references.citation: Electrophoresis. 2000 Nov;21(17):3666-72
references.pmid: 11271485
references.citation: Nat Rev Drug Discov. 2004 May;3(5):401-16
references.pmid: 15136788
references.citation: FASEB J. 2007 Feb;21(2):325-32
references.pmid: 17267386
references.citation: Arch Dermatol Res. 2002 Jul;294(4):190-7
references.pmid: 12111350
references.citation: Nat Rev Immunol. 2002 Oct;2(10):787-95
references.pmid: 12360216
references.citation: J Immunol. 1996 Feb 1;156(3):1143-50
references.pmid: 8557991
references.citation: J Immunol. 2007 Apr 1;178(7):4557-66
references.pmid: 17372014
references.citation: J Clin Invest. 2007 Jan;117(1):175-84
references.pmid: 17200717
references.citation: N Engl J Med. 1999 Feb 11;340(6):448-54
references.pmid: 9971870
references.citation: Nat Med. 1999 Jun;5(6):698-701
references.pmid: 10371510
references.citation: Crit Care Med. 2002 Oct;30(10):2284-94
references.pmid: 12394957
references.citation: J Immunol. 2001 Oct 15;167(8):4293-302
references.pmid: 11591752
references.citation: J Clin Invest. 1995 Apr;95(4):1628-34
references.pmid: 7706470
references.citation: Immunol Today. 1995 Dec;16(12):595-603
references.pmid: 8579753
references.citation: Biochim Biophys Acta. 2006 Feb;1762(2):164-80
references.pmid: 16236486
references.citation: Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8676-80
references.pmid: 1528880
references.citation: Nat Rev Immunol. 2003 Jan;3(1):23-35
references.pmid: 12511873
references.citation: J Clin Invest. 2001 Oct;108(7):957-62
references.pmid: 11581295
references.citation: J Immunol. 1992 Apr 1;148(7):2201-6
references.pmid: 1347551
references.citation: Nature. 2001 Dec 20-27;414(6866):916-20
references.pmid: 11780065
references.citation: Methods Enzymol. 1988;159:159-72
references.pmid: 2842582
references.citation: Blood. 2008 Apr 15;111(8):4184-92
references.pmid: 18218853
references.citation: Infect Immun. 2007 Aug;75(8):4148-57
references.pmid: 17526748
references.citation: IUBMB Life. 2006 Dec;58(12):703-15
references.pmid: 17424909
references.citation: J Immunol Methods. 1994 Sep 14;174(1-2):83-93
references.pmid: 8083541
references.citation: J Clin Invest. 2005 Jan;115(1):56-65
references.pmid: 15630444
references.citation: IUBMB Life. 2004 Jun;56(6):343-7
references.pmid: 15370882
references.citation: J Exp Med. 2002 Dec 2;196(11):1515-21
references.pmid: 12461086
references.citation: J Immunol. 2001 Nov 1;167(9):5294-303
references.pmid: 11673545
references.citation: J Immunol. 1996 Sep 15;157(6):2577-85
references.pmid: 8805660
references.citation: Mol Pharmacol. 1991 Feb;39(2):233-8
references.pmid: 1847496
references.citation: Biochemistry. 1990 May 8;29(18):4312-7
references.pmid: 2161683
references.citation: Ser Haematol. 1970;3(2):132-44
references.pmid: 4943387
references.citation: Kidney Int. 2007 Aug;72(3):290-9
references.pmid: 17440493
references.citation: Curr Med Chem. 2004 Feb;11(4):465-76
references.pmid: 14965227
references.citation: Shock. 2006 Nov;26(5):477-84
references.pmid: 17047518